NRx Pharmaceuticals (NASDAQ:NRXP) Shares Down 0.8% – Time to Sell?

Posted by Maddie Sorensen on Oct 24th, 2024

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Get Free Report)’s share price was down 0.8% during mid-day trading on Monday . The company traded as low as $1.23 and last traded at $1.24. Approximately 407,132 shares traded hands during trading, an increase of 101% from the average daily volume of 202,154 shares. The stock had previously closed at $1.25.

Analysts Set New Price Targets

A number of research firms recently weighed in on NRXP. EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday. HC Wainwright upped their target price on NRx Pharmaceuticals from $2.00 to $19.00 and gave the company a “buy” rating in a report on Monday, August 5th. Finally, Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a report on Thursday, September 12th.

Read Our Latest Stock Report on NRXP

NRx Pharmaceuticals Price Performance

The stock has a market capitalization of $12.95 million, a price-to-earnings ratio of -0.38 and a beta of 1.25. The business has a fifty day moving average of $1.64 and a 200 day moving average of $2.54.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.06. On average, equities research analysts expect that NRx Pharmaceuticals, Inc. will post -3.25 EPS for the current year.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.